Wanbury
WANBURY NSE
Wanbury
HealthcareNSE: WANBURY BSE: 524212 Pharmaceuticals & Biotechnology
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹827 Cr
Volatility
Moderate
P/E Ratio
14.95
EBITDA
₹79.80 Cr
Return on Equity
51.51%
Debt to Equity
1.56
Book Value
₹41.32
52W High
₹358.85
52W Low
₹161.5
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company has delivered good profit growth of 47.8% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 82.2%
Weaknesses
4- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 10.6% over past five years.
- Tax rate seems low
- Promoters have pledged 62.2% of their holding.
Growth Rate
Revenue Growth
4.22% lower than
3Y
Net Income Growth
-45.54% lower than
3Y
Cash Flow Change
556% higher than
3Y
ROE
-74.28% lower than
3Y
ROCE
-57.95% higher than
3Y
EBITDA Margin (Avg.)
5% lower than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 146 | 144 | 146 | 139 | 131 | 161 | 133 | 172 | 163 | 160 | 162 | 165 | 166 |
| Expenses | 133 | 127 | 124 | 121 | 120 | 141 | 120 | 142 | 139 | 134 | 136 | 135 | 149 |
| Operating Profit | 13.35 | 17.34 | 21.15 | 18.16 | 10.98 | 20.01 | 13.95 | 29.63 | 24.44 | 25.78 | 26.68 | 29.84 | 16.23 |
| OPM % | 9.13% | 12% | 14.54% | 13.03% | 8.37% | 12.41% | 10.45% | 17.23% | 14.98% | 16.11% | 16.42% | 18.13% | 9.8% |
| Other Income | 0.62 | 0.76 | 0.69 | 0.93 | 0.94 | 1.63 | 0.84 | 1.84 | 0.35 | 0.2 | 0.18 | -3.39 | 0.36 |
| Interest | 5.79 | 7.67 | 8.26 | 7.46 | 7.59 | 10.15 | 10.17 | 9.04 | 7.54 | 7.12 | 7.26 | 8.06 | 7.97 |
| Depreciation | 3.18 | 3.24 | 3.32 | 3.28 | 3.29 | 3.32 | 3.32 | 3.37 | 3.64 | 3.7 | 3.74 | 3.23 | 4.04 |
| PBT | 5 | 7.19 | 10.26 | 8.35 | 1.04 | 8.17 | 1.3 | 19.06 | 13.61 | 15.16 | 15.86 | 15.16 | 4.58 |
| Tax % | 6% | -2.5% | -0.19% | 3.23% | 0% | 1.84% | 5.38% | -6.3% | 0.88% | -0.13% | 0.69% | -43.14% | 29.26% |
| Net Profit | 4.69 | 7.36 | 10.27 | 8.08 | 1.04 | 8.02 | 1.22 | 20.26 | 13.49 | 15.18 | 15.76 | 21.7 | 3.24 |
| EPS in Rs | 1.43 | 2.25 | 3.14 | 2.47 | 0.32 | 2.45 | 0.37 | 6.18 | 4.1 | 4.35 | 4.52 | 6.21 | 0.93 |
Profit & Loss
| Particulars | Mar 2015 6m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 250 | 420 | 432 | 370 | 391 | 367 | 392 | 511 | 500 | 578 | 600 | 650 | 653 |
| Expenses | 228 | 387 | 414 | 438 | 375 | 344 | 374 | 475 | 476 | 506 | 523 | 544 | 554 |
| Operating Profit | 21 | 34 | 19 | -68 | 16 | 23 | 18 | 36 | 23 | 72 | 77 | 107 | 99 |
| OPM % | 9% | 8% | 4.3% | -18% | 4.1% | 6% | 4.7% | 7% | 4.7% | 12% | 13% | 16% | 15% |
| Other Income | 6 | 0 | 90 | 76 | 9 | 84 | 2 | 77 | 0 | 1 | 3 | -3 | -3 |
| Interest | 19 | 32 | 36 | 31 | 40 | 33 | 23 | 21 | 21 | 29 | 37 | 30 | 30 |
| Depreciation | 5 | 9 | 10 | 10 | 10 | 10 | 10 | 11 | 12 | 13 | 13 | 14 | 15 |
| PBT | 4 | -7 | 62 | -32 | -25 | 65 | -12 | 81 | -10 | 31 | 30 | 60 | 51 |
| Tax % | 28% | 0% | 1% | -1% | -1% | 0% | 2% | 0% | 1% | 1% | -3% | -11% | — |
| Net Profit | 3 | -7 | 62 | -32 | -25 | 64 | -13 | 81 | -10 | 30 | 31 | 66 | 56 |
| EPS in Rs | 1.61 | -3.52 | 26.71 | -13.49 | -10.48 | 25.79 | -5.04 | 24.94 | -3.18 | 9.28 | 9.32 | 18.93 | 16.01 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 20 | 20 | 23 | 24 | 24 | 25 | 25 | 33 | 33 | 33 | 33 | 35 |
| Reserves | -188 | -183 | -151 | -183 | -207 | -143 | -156 | -30 | -40 | -5 | 26 | 110 |
| Borrowings | 381 | 373 | 273 | 224 | 233 | 164 | 166 | 74 | 68 | 116 | 179 | 226 |
| Other Liabilities | 182 | 176 | 265 | 207 | 235 | 231 | 253 | 275 | 241 | 199 | 176 | 147 |
| Total Liabilities | 394 | 386 | 411 | 271 | 285 | 277 | 288 | 351 | 302 | 343 | 414 | 518 |
| Fixed Assets | 164 | 180 | 186 | 178 | 172 | 164 | 167 | 167 | 167 | 167 | 201 | 229 |
| CWIP | 19 | 14 | 10 | 10 | 9 | 14 | 11 | 2 | 2 | 3 | 5 | 25 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 212 | 192 | 215 | 83 | 103 | 99 | 109 | 182 | 133 | 173 | 208 | 263 |
| Total Assets | 394 | 386 | 411 | 271 | 285 | 277 | 288 | 351 | 302 | 343 | 414 | 518 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 40 | 43 | 43 | 32 | 30 | 44 | 17 | 41 | 20 | 5 | 26 | 32 |
| Investing | -5 | -20 | -13 | -1 | -3 | 64 | 8 | 1 | -9 | -17 | -51 | -56 |
| Financing | -30 | -28 | -27 | -33 | -27 | -108 | -17 | -29 | -32 | 14 | 26 | 22 |
| Net Cash Flow | 5 | -5 | 3 | -2 | 0 | 0 | 7 | 13 | -21 | 2 | 1 | -2 |
| Free Cash Flow | 35 | 22 | 29 | 30 | 25 | 36 | 12 | 42 | 7 | -9 | -22 | -28 |
| CFO/OP | 187 | 129 | 234 | -49 | 188 | 188 | 97 | 113 | 86 | 7 | 35 | 30 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 144 | 65 | 71 | 29 | 41 | 50 | 32 | 45 | 50 | 56 | 70 | 80 |
| Inventory Days | 103 | 69 | 63 | 27 | 36 | 25 | 41 | 60 | 26 | 43 | 47 | 67 |
| Days Payable | 300 | 171 | 259 | 173 | 208 | 252 | 220 | 218 | 178 | 196 | 172 | 142 |
| Cash Conversion Cycle | -54 | -37 | -124 | -117 | -131 | -176 | -147 | -112 | -101 | -96 | -55 | 6 |
| Working Capital Days | -139 | -123 | -164 | -251 | -230 | -211 | -227 | -134 | -129 | -37 | 3 | 17 |
| ROCE % | — | 12% | 55% | -1% | 26% | 31% | 23% | 46% | 17% | 58% | 34% | 31% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Wanbury insights
35 extracted metrics + investor summaries across FY15–FY26.
Documents
1
Clarification sought from Wanbury Ltd
16 Jul - Exchange has sought clarification from Wanbury Ltd on July 16, 2026 with reference to significant movement in price, in order to ensure that investors have … 16 Jul - Exchange has sought clarification from Wanbury Ltd on July 16, 2026 with reference to significant movement in price, in order to ensure that investors have …
2
Board Meeting Intimation for Notice Of Board Meeting For Approving The Audited Financial Results & Statements Of The Company For The Fourth Quarter And Year Ended 31St March, 2026.
5 May - Board meeting on 14 May 2026 to approve Q4 and FY2026 audited financial results. 5 May - Board meeting on 14 May 2026 to approve Q4 and FY2026 audited financial results.
3
Announcement under Regulation 30 (LODR)-Press Release / Media Release
28 Apr - Wanbury’s Patalganga site completed MFDS inspection with zero observations on April 7-9, 2026. 28 Apr - Wanbury’s Patalganga site completed MFDS inspection with zero observations on April 7-9, 2026.
4
Announcement under Regulation 30 (LODR)-Press Release / Media Release
28 Apr - Wanbury’s Patalganga site completed MFDS inspection with zero observations on April 7-9, 2026. 28 Apr - Wanbury’s Patalganga site completed MFDS inspection with zero observations on April 7-9, 2026.
5
Compliances-Reg.24(A)-Annual Secretarial Compliance
1d - Wanbury’s FY2026 secretarial compliance report notes minor SEBI/stock exchange non-compliances and paid fines. 1d - Wanbury’s FY2026 secretarial compliance report notes minor SEBI/stock exchange non-compliances and paid fines.
Frequently Asked Questions about Wanbury
What does Wanbury Ltd do?
Incorporated in 1988, Wanbury Ltd is in the business of pharmaceutical and related activities, including research[1]
Where is Wanbury Ltd (WANBURY) listed?
Wanbury Ltd trades as WANBURY on the NSE and under code 524212 on the BSE.
Which sector does Wanbury Ltd belong to?
Wanbury Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Wanbury Ltd?
Wanbury Ltd has a market capitalisation of ₹827.02 Cr, which places it in the Small Cap band.
What is the PE ratio of Wanbury Ltd?
Wanbury Ltd trades at a PE ratio of 14.95, against a book value of ₹41.32 per share.
What is the 52-week high and low of Wanbury Ltd?
Over the last 52 weeks Wanbury Ltd has traded between ₹161.5 and ₹358.85.
What is the Return on Equity (ROE) of Wanbury Ltd?
Wanbury Ltd reported a return on equity of 51.51%. Its debt-to-equity ratio is 1.56.
Company Information
Incorporated in 1988, Wanbury Ltd is in the business of pharmaceutical and related activities, including research[1]
Website wanbury.com
CEO Mr. Mohan Kumar Rayana
Employees 1,382
Listed 2007-01-29
Face Value ₹ 10
Issued Size 3,48,76,998
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/WANBURY.md for Wanbury Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.